CLEVIPREX® (clevidipine) pharmacology and mechanism of action
![Cleviprex vials](https://cleviprex.com/wp-content/uploads/bottles-hero-1.webp)
CLEVIPREX rapidly lowers arterial blood pressure1
![Down Arrows](https://cleviprex.com/wp-content/uploads/icon-titratable.png)
Titratable, fast onset of action1
CLEVIPREX begins to reduce SBP within 2 minutes of initiation dose. An approximately 1 to 2 mg/h increase will generally produce an additional 2 to 4 mm Hg decrease in SBP.
![](https://cleviprex.com/wp-content/uploads/icon-1minute-1.png)
~1-minute half-life1
CLEVIPREX has a half-life of ~1 minute. In most patients, full recovery of BP is achieved 5 to 15 minutes after the infusion is stopped.
The pharmacology of CLEVIPREX1
CLEVIPREX is titrated to the desired reduction in BP. The effect of CLEVIPREX appears to plateau at approximately 25% of baseline SBP. The infusion rate for which half the maximal effect is observed is approximately 10 mg/h.
![](https://cleviprex.com/wp-content/themes/html5-blank/img/poster-pharmacology.webp)
Mechanism of action1
CLEVIPREX works by selectively dilating arterial smooth muscle via calcium channel blockade, reducing systemic vascular resistance without affecting preload.
![](https://cleviprex.com/wp-content/themes/html5-blank/img/poster-MOA.jpg)
Stroke Guidelines
CLEVIPREX has been recommended in the AHA/ASA Acute Ischemic Stroke Guidelines since 2018.3
Proven efficacy in clinical studies1,2,4-6
CLEVIPREX provided BP reduction in a range of patients and in various clinical settings.
Individualized, titratable administration1
CLEVIPREX offers low-volume, non–weight-based dosing that is independent of renal or hepatic function.